Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Sunday, September 6, 2026

A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

 With your extra risk of Alzheimers is your competent? doctor knowledgeable about this? 

NO? So, PURE INCOMPETENCE! 

Good to know to get rid of him/her now!

1. A documented 33% dementia chance post-stroke from an Australian study?   May 2012.

2. Then this study came out and seems to have a range from 17-66%. December 2013.`    

3. A 20% chance in this research.   July 2013.

4. Dementia Risk Doubled in Patients Following Stroke September 2018 

The latest here:

A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease 

Study Overview

Brief Summary
The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment [MCI] to mild dementia due to AD).
Official Title
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease (MCI to Mild Dementia Due to AD)
Conditions
Alzheimers Disease
Intervention/Treatment
  • Drug: Trontinemab
  • Other: Placebo
Other Study ID Numbers
  • WN45447
Study Start (Actual)
2025-11-12
Primary Completion (Estimated)
2028-06-07
Study Completion (Estimated)
2028-06-07
Enrollment (Estimated)
800
Study Type
Interventional
Phase
Phase 3

MedlinePlus related topics:  Mild Cognitive Impairment  Alzheimer's Caregivers 
FDA Drug and Device Resources

Contacts and Locations

This section provides contact details for people who can answer questions about joining this study, and information on where this study is taking place.

To learn more, please see the Contacts and Locations section in How to Read a Study Record.

Study Contact

Name: Reference Study ID Number: WN45447 https://forpatients.roche.com/ No attachments to email below.

Phone Number: 888-662-6728

Email: global-roche-genentech-trials@gene.com

Study Contact Backup

Name: Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry

This study has 150 locations
Posted by at
Labels: , , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)